Monitor A Drug Treatment Offering A Greater Reduction In The Number Of UUI Episodes Per Week Than Extended-Release Tolterodine For The Treatment Of Urge Urinary Incontinence

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c92558) has announced the addition of new Decision Resources report Target Product Profiles 2008: Physician Insights on Key Attributes - Urge Urinary Incontinence to their offering.

Using Target Product Profiles in Your Market Strategy

Our Target Product Profiles qualitatively predict the market potential of a drug fulfilling a key unmet need. This information is critical for evaluating the impact of clinical attributes on physician prescribing of emerging agents, whether the emerging drug is your own or a competitor’s. Examples of how to use the information you will find in this report are highlighted below:

-- For companies who are developing a drug with some of the characteristics we are testing, our survey results reveal the standards that surveyed physicians expect the remainder of the drug's clinical profile to meet. Our analysis begins to uncover physician-expected drug attributes as well as acceptable trade-offs in emerging therapies. Our primary research with practicing physicians includes this emerging therapy's anticipated patient share, projected use by line of therapy, and forecasted sales.

-- For companies that already have a drug launched for the indication in question, our data and analysis show the impact an emerging drug would have on their brand's market. Not only does our research reveal which existing brands would be replaced by a drug meeting the Target Product Profile le, but it also clearly outlines whether any drugs in the pipeline will meet the criteria laid out by physicians to challenge the existing sales leader. This knowledge gives existing brands the information they need to protect their share, either through new clinical trials aimed at end points physicians say are critical differentiators or by aggressive marketing of brand attributes that emerging agents will not be able to beat.

-- For companies looking to enter a disease through licensing or acquisition, the challenge of sifting through tens or hundreds of early-stage candidates can be daunting. Our Target Product Profiles can quickly show business development teams the clinical attributes that are unique versus products already on the market, and our primary research with physicians quickly identifies likely share and market potential to give a first glimpse at valuation.

Because all of our Target Product Profiles are designed to be attainable within the next decade, our research can be a fast and efficient way to whittle the field of potential licensing candidates down to the most valuable few.

Report Contents

The Target Product Profile le reports are divided into two sections. The first section, “Etiology and Pathophysiology,” offers a high-level view of the genetic and environmental causes of the disease under study, as well as the subsequent symptoms and clinical effects that result. This section is intended to give the reader a clear view of the physical and biochemical pathways that are known, or suspected, to be causative to disease onset or progression. These pathways, therefore, are common targets for drug therapy; where possible, we identify the molecular targets against which current or emerging drugs act.

The second section, “Target Product Profile le Summary,” begins with an overview of the drug development landscape and the attributes on which investigators are focusing. Based on this analysis, as well as the clinical end points that practicing physicians say are most influential in their prescribing decision, our analysts define a key unmet need that could be addressed within the next ten years. Our Target Product Profile les are a set of quantified performance measures against key clinical end points and attributes that physicians build themselves. Our analysis of physician-desired attributes identifies areas of potential trade-offs versus those attributes that are either expected in new agents or are fully satisfied by current therapies. This section concludes with an analysis of high profile agents currently in the pipeline (“Competitors to Watch” and “Emerging Product Profiles”).

Using surveyed physicians’ estimates of these agents’ usage as inputs, our analysis integrates our extensive knowledge of the competitive landscape and non-clinical market hurdles to determine the market potential of these agents and their threat to current brands.

Content Outline:

Introduction

Using Target Product Profiles in Your Market Strategy

Report Contents

Target Product Profile Methodology

Etiology and Pathophysiology

Overview

Anatomy

The Bladder

Role of the Ureters: Creation of a Control Valve

Role of the Bladder Neck: Controlling the Bladder/Abdominal Pressure Balance

The Urethra

Involuntary and Voluntary Control of Micturition

Pathophysiology

Classification

Other Types of Incontinence and Their Relationship to UUI

Etiology

Detrusor Overactivity

Risk Factors

Target Product Profile Discussion--Urge Urinary Incontinence

Target Product Profile Summary for Urge Urinary Incontinence--2011

Assessing Drug Development Opportunities

Physician Survey Results

Efficacy

Safety and Tolerability

Delivery

Estimated Patient Share

Pricing Potential

Forecasted 2016 Pricing Environment

Competitors to Watch

Emerging Product Profiles

For more information visit http://www.researchandmarkets.com/reports/c92558